Destiny Pharma (LON:DEST) Hits New 1-Year Low at $2.00

Destiny Pharma plc (LON:DEST)’s share price reached a new 52-week low on Friday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2.44 ($0.03), with a volume of 3265595 shares changing hands. The stock had previously closed at GBX 2.75 ($0.04).

Analyst Ratings Changes

Separately, Shore Capital restated a “house stock” rating on shares of Destiny Pharma in a research note on Monday, July 15th.

Destiny Pharma Price Performance

The business’s 50 day moving average is GBX 10.74 and its 200 day moving average is GBX 27.70. The stock has a market cap of £2.33 million, a price-to-earnings ratio of -35.17 and a beta of 0.31.

Destiny Pharma Company Profile

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.